Hypercoagulability and hyperfibrinolysis in patients with melanoma

Bottasso, B.; Mari, Daniela; Coppola, R.; Santoro, Nicola; Vaglini, M.; Mannucci, Pier Mannuccio

doi:10.1016/0049-3848(96)00006-0

Cited by 26 publications

(24 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of circulating biomarkers resembling activated coagulation and fibrinolytic systems such as fibrinogen (F), fibrin(ogen) split products and DD have been associated with decreased survival for several tumor types in previous studies [11][12][13]. Researches on melanoma patients examining the relationship between activated hemostatic system and prognosis have yielded similar results [14][15][16]. Sufficient evidence of such an advantage has not been found for cancer patients in general.…”

Section: Introductionmentioning

confidence: 59%

Clinical and prognostic significance of coagulation assays in melanoma

et al. 2012

View full text Add to dashboard Cite

The activation of coagulation and fibrinolysis is frequently found among cancer patients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests for melanoma patients. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin activity (PTA), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were carried out. This prospective study included 61 melanoma patients [stage I-II (n=10), stage III (n=14), stage IV (n=37), M1c (n=26) disease], and 50 healthy controls. It included 34 (56%) men, median age 53 years, range 16-88 years. Over half of the patients (54%) were in the metastatic stage and most of them (70%) had M1c. The plasma level of pretreatment blood coagulation tests including DD, F, APTT, INR levels, and PLT counts showed a statistically significant difference between the patient and the control group (P<0.001 for all, but P=0.049 for INR). The levels of INR, DD, F, and PLT counts were higher and APTT was lower in the melanoma group, whereas the PT and PTA levels did not show any significant difference. There was a significant association between PT, PTA, INR, and PLT levels and the age of the patient. Patients with node metastasis in M0 disease had higher levels of PTA and PLT counts (P=0.002 and 0.048, respectively) and lower levels of PT and INR (P=0.056 and 0.046, respectively). The M1c patients tended to have higher plasma F levels (437 vs. 297 mg/dl, P=0.055) than M1a and M1b patients. The 1-year survival rate for all patients was 70%. In association with distant metastasis, advanced metastatic stage (M1c), elevated lactate dehydrogenase, and erythrocyte sedimentation rate, only elevated plasma F levels had a significantly adverse effect on survival among the coagulation parameters (P=0.031). The 1-year survival rates for patients with high and normal F levels were 58 and 88%, respectively. In conclusion, changes in the coagulation-fibrinolytic system are often present in melanoma and elevation in the plasma F level is associated with decreased survival.

show abstract

Section: Introductionmentioning

confidence: 59%

Clinical and prognostic significance of coagulation assays in melanoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In a series of coagulation markers tested, only the fibrinogen ␣-chain was significantly increased in gastric cancer, and it was correlated with tumor T, N, and M stages (38 ). Similarly, the fibrinogen ␣-chain peptide has been found to be significantly increased in melanoma (39 ). In a clinical trial of chemotherapy, treatment with mopidamol was associated with a statistically significant prolongation of survival in patients with lung cancer, an effect correlated with the reduction in mean plasma fibrinogen concentration (40 ).…”

Section: Discussionmentioning

confidence: 95%

Oral Cancer Plasma Tumor Marker Identified with Bead-Based Affinity-Fractionated Proteomic Technology

Cheng¹,

Chen²,

Chien

et al. 2005

Clinical Chemistry

130

View full text Add to dashboard Cite

Background: There is no plasma marker for detecting oral cancer, one of the most frequent cancers worldwide. We developed a bead-based affinity-fractionated proteomic method to discover a novel plasma marker for oral cancer. Methods: Affinity purification of heparinized plasma with magnetic beads and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis were used to screen potential oral cancer markers. We compiled MS protein profiles for 57 patients with oral cancer and compared them with profiles from 29 healthy controls. The spectra were analyzed statistically using flexAnalysis TM and ClinProt TM bioinformatic software. In each MS analysis, the peak intensities of interest were normalized with an internal standard (adrenocorticotropic hormone 18 -39). For identification, affinity bead-purified plasma protein was subjected to MALDI TOF/TOF analysis followed by Mascot identification of the peptide sequences and a search of the National Center for Biotechnology Information protein database. Results: To optimize MALDI-TOF analysis based on the best discriminator of the cancer and control spectra, copper-chelated beads were used for plasma protein profiling. The within-and between-run CVs for assays were <4% and 7%, respectively. Six markers that differentiated between cancer and control spectra were found,

show abstract

“…A case of internal jugular vein thrombosis associated with metastatic papillary carcinoma of the thyroid has been reported, 86 and an hypercoagulable state has been described in patients with melanoma. 8 The literature reports a case of internal carotid occlusion associated with malignant peritoneal mesothelioma.…”

Section: Introductionmentioning

confidence: 99%